Clinical Evaluation of CS-866 (Olmesartan Medoxomil), a novel Angiotensin II Receptor Antagonisit, in Patients with Mild-to-moderate Essential Hypertension-Pre-pilot Phase II Study-
|
Accession number;03A0708403
|
| Title;Clinical Evaluation of CS-866 (Olmesartan Medoxomil), a novel Angiotensin II Receptor Antagonisit, in Patients with Mild-to-moderate Essential Hypertension-Pre-pilot Phase II Study- |
| Author;
OGIHARA TOSHIO
(Osaka Univ., Med. Sch.)
ICHIKAWA SHUICHI
(Kita-Kanto Junkanki Byoin)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.19;NO.9;PAGE.969-981(2003)
|
| Figure&Table&Reference;FIG.4, TBL.10, REF.12 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;A pre-pilot study was conducted to assess the efficacy and safety of the new angiotensin II receptor antagonist CS-866 (olmesartan medoxomil) for the treatment of mild to moderate essential hypertension. Patients were treated once daily with 5-20mg CS-866 tablets in a stepwise dose-escalating regimen, 3 to 5 days for each dose. 1) Blood pressure significantly decreased 6 days after initial administration, and remained stable thereafter. 2) In evaluating the rate of decreased blood pressure, 83.3% of the cases were judged as "decreased". 3) Concerning adverse events, a subjective symptom was seen in 1 patient, abnormalities in laboratory parameters were seen in 2 patients, and accidental symptoms were seen in 2 patients. Of these, adverse reactions comprised 1 case each of malaise and increased potassium levels. 4) The overall safety rating gave results of "no problem" of 66.7%, and "slightly problematic" of 33.3%. 5) Usefulness rating gave results of "useful" of 83.3%. We concluded that CS-866 at a daily dose of 5mg to 20mg is well tolerable in treating mild to moderate essential hypertension, and once daily administration achieves continuous antihypertensive effects for 24 hours. (author abst.) |
|
|
|
Related Articles;
|
|
